Want to see NDRA full AI Analyst Report?
NDRA Stock Chart & Stats
$4.86
-$0.08(-1.65%)
At close: 4:00 PM EDT
$4.86
-$0.08(-1.65%)
Day’s Range― - ―
52-Week Range$2.96 - $9.85
Previous Close$4.78
Volume5.95K
Average Volume (3M)514.97K
Market Cap
$5.97M
Enterprise Value$5.68
Total Cash (Recent Filing)$356.46K
Total Debt (Recent Filing)$461.21K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 17, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.16
Shares Outstanding1,270,077
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside414.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt relative to equity reduces near-term solvency pressure and preserves financing optionality. For a cash-burning medtech developer, modest leverage lowers default risk, making it easier to secure additional capital or debt on reasonable terms during the multi-quarter commercialization or strategic-transition period.
Access To Substantial Capital Via MergerThe proposed merger includes a committed $50M private placement to fund the combined business, materially improving liquidity headroom. Structural capital commitments support multi-quarter development and project funding needs, reducing execution risk tied to ongoing cash burn and enabling strategic investment beyond current resources.
Strategic Partner Backing And Project LinkageAlignment with ASP Isotopes/Noble brings operational backing, potential access to large project-level financing and commercial contracts. That shifts ENDRA from a standalone medtech developer toward a cash-flow oriented platform tied to energy/helium projects, a structural change that can sustainably transform revenue and capital profiles if executed.
Bears Say
No Revenue And Large Recurring LossesAbsence of a repeatable revenue base and persistent operating losses signal the company has not yet proven commercial viability. Over multiple quarters this undermines path to profitability, increases dependency on external financing, and elevates long-term dilution and business continuity risk if new revenue streams fail to materialize.
Heavy Cash Burn And Shrinking EquitySizable negative operating and free cash flow combined with materially reduced equity heighten solvency and dilution risk over coming quarters. Even with some improvement versus prior years, continued negative cash generation makes the company reliant on dilutive financings or strategic transactions to sustain operations and satisfy listing requirements.
Control Transfer And Major Dilution For Legacy ShareholdersThe proposed governance and ownership structure centralizes control with ASP Isotopes and relegates legacy shareholders to a small residual stake. This structural shift reduces minority influence, raises takeover/interest-alignment concerns, and can materially change capital allocation and strategic priorities to the detriment of original shareholders.
ENDRA Life Sciences News
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $2.96 and its highest was $9.85 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
ENDRA Life Sciences Inc’s market cap is $5.97M.
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 10 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on May 18, 2026. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Undervalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -0.84.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 1,270,077 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of -$1.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.129%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
NDRA Stock 12 Month Forecast
Average Price Target
$25.00
▲(414.40% Upside)
Technical Analysis
Ownership Overview
31.76% Insiders
0.83% Mutual Funds
4.09% Other Institutional Investors
62.74% Public Companies and
Individual Investors